c-ABL-IN-5

c-ABL-IN-5

• UNSPSC Description: c-ABL-IN-5 is a selective c-Abl inhibitor with neuroprotective effects. c-ABL-IN-5 has blood-brain barrier penetrability, metabolic stability and good pharmacokinetic properties. When c-ABL-IN-5 is labeled with [18F] (compound [18F]3), it can be used as a tracer to evaluate disease-modifying efficacy by complementary positron emission tomography (PET). c-ABL-IN-5 can be used in the study of neurodegenerative diseases such as Parkinson's disease (PD)[1].
• Target Antigen: Bcr-Abl
• Type: Reference compound
• Related Pathways: Protein Tyrosine Kinase/RTK
• Applications: Neuroscience-Neurodegeneration
• Field of Research: Neurological Disease
• Assay Protocol: https://www.medchemexpress.com/c-abl-in-5.html
• Solubility: 10 mM in DMSO
• Smiles: O=C(NC1=CN2C=C(C=CC2=N1)C3=CC=CC=C3CCF)[C@H]4[C@H](C4)F
• Molecular Weight: 341.35
• References & Citations: [1]Stéen EJL, et al. Development of 18F-Labeled PET Tracer Candidates for Imaging of the Abelson Non-receptor Tyrosine Kinase in Parkinson's Disease. J Med Chem. 2023 Sep 15.. .
• Shipping Conditions: Room temperature
• Clinical Information: No Development Reported